6-methyl-pyridine-2,3,4-triyltriamine | 856835-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-methyl-pyridine-2,3,4-triyltriamine
• 英文别名: 6-Methyl-pyridin-2,3,4-triyltriamin；6-Methylpyridine-2,3,4-triamine
• CAS: 856835-00-2
• 化学式: C₆H₁₀N₄
• mdl: MFCD13176253
• 分子量: 138.172
• InChiKey: ZDDXYQCYGIUERO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  91
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 6-methyl-pyridine-2,3,4-triyltriamine 在 水 、 copper diacetate 作用下， 生成 5-methyl-1(3)H-imidazo[4,5-b]pyridin-7-ylamine
  参考文献：
  名称：

  Salemink; van der Want, Recueil des Travaux Chimiques des Pays-Bas, 1949, vol. 68, p. 1013,1024

  摘要：

  DOI：
• 作为产物：
  描述：

  6-methyl-3-nitro-pyridine-2,4-diyldiamine 在 sodium sulfide 、 水 作用下， 生成 6-methyl-pyridine-2,3,4-triyltriamine
  参考文献：
  名称：

  Salemink; van der Want, Recueil des Travaux Chimiques des Pays-Bas, 1949, vol. 68, p. 1013,1024

  摘要：

  DOI：

文献信息

• COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT
  申请人：Stehouwer Jeff

  公开号：US20110305636A1

  公开（公告）日：2011-12-15

  Briefly described, embodiments of this disclosure include compounds as described herein, labeled compounds as described herein, pharmaceutical composition including compounds described herein, methods of imaging, method of forming a compound as described herein, and the like. In particular, embodiments of the disclosure include a series of triamino-pyridine derivatives and labeled triamino-pyridine derivatives, methods of synthesizing these compounds, intermediate compounds, methods of treatment using these compounds, methods of imaging, diagnosing, localizing, monitoring, and/or assessing a condition (e.g., corticotropin releasing factor type-1 (CRF1)) and/or related biological events, using triamino-pyridine derivatives, and the like. In addition, the present disclosure includes compositions (e.g., labeled triamino-pyridine derivatives that are ligands for the CRF1 receptor) used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging or SPECT imaging).
• US8551996B2
  申请人：——

  公开号：US8551996B2

  公开（公告）日：2013-10-08
• [EN] COMPOUNDS, COMPOSITIONS, METHODS OF SYNTHESIS, AND METHODS OF TREATMENT<br/>[FR] COMPOSÉS, COMPOSITIONS, PROCÉDÉS DE SYNTHÈSE ET PROCÉDÉS DE TRAITEMENT
  申请人：UNIV EMORY

  公开号：WO2010096426A2

  公开（公告）日：2010-08-26

  Briefly described, embodiments of this disclosure include compounds as described herein, labeled compounds as described herein, pharmaceutical composition including compounds described herein, methods of imaging, method of forming a compound as described herein, and the like. In particular, embodiments of the disclosure include a series of triamino-pyridine derivatives and labeled triamino-pyridine derivatives, methods of synthesizing these compounds, intermediate compounds, methods of treatment using these compounds, methods of imaging, diagnosing, localizing, monitoring, and/or assessing a condition (e.g., corticotropin releasing factor type-1 (CRF1)) and/or related biological events, using triamino-pyridine derivatives, and the like. In addition, the present disclosure includes compositions (e.g., labeled triamino-pyridine derivatives that are ligands for the CRF1 receptor) used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging or SPECT imaging).
• Salemink; van der Want, Recueil des Travaux Chimiques des Pays-Bas, 1949, vol. 68, p. 1013,1024
  作者：Salemink、van der Want

  DOI：——

  日期：——